Research and Markets (http://www.researchandmarkets.com/research/f4hxmb/thalassemia) has announced the addition of the "Thalassemia - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Thalassemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thalassemia and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Acceleron Pharma, Inc.
- Acetylon Pharmaceuticals, Inc.
- Acino Pharma AG
- Alnylam Pharmaceuticals, Inc.
- Bluebird bio, Inc.
- Emmaus Medical, Inc.
- Errant Gene Therapeutics, LLC
- Gamida Cell Ltd.
- Incyte Corporation
- IRBM Science Park SpA
- Isis Pharmaceuticals, Inc.
- Johnson & Johnson
- Kiadis Pharma B.V.
- La Jolla Pharmaceutical Company
- PharmaEssentia Corporation
- Protagonist Therapeutics Inc.
- Sangamo BioSciences, Inc.
Drug Profiles
- ACY-957
- ALN-TMP
- Antisense Oligonucleotides to Inhibit BCL11A and KLF1 for Hematological Disorders
- ATIR-201
- BB-305
- BtX-13
- CNTO-530
- CordIn
- Gene Therapy for Sickle Cell Disease and Beta Thalassemia
- Gene Therapy for Sickle Cell Disease and Thalassemia
- glutamine
- ISIS-TMPRSS6LRx
- LJPC-401
- luspatercept
- M-012
- NiCord
- PB-04
- Peptide Agonists of Hepcidin for Beta-Thalassemia and Juvenile Hemochromatosis
- Project x-1450
- ruxolitinib phosphate
- SCD-101
- Small Molecule for Beta Thalassemia and Sickle Cell Anemia
- Small Molecule to Inhibit Histone Deacetylase 1 for Beta-Thalassemia
- Small Molecules to Inhibit PRMT5 for Haemoglobinopathies and Solid Tumours
- sotatercept
- Stem Cell Therapy for Beta Thalassemia
- Stem Cell Therapy to Activate Beta Globin for Thalassemia
- Thalagen
For more information visit http://www.researchandmarkets.com/research/f4hxmb/thalassemia
View source version on businesswire.com: http://www.businesswire.com/news/home/20151126005460/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector:
Hematological
